1Gaytant MA,Steegers EA,Semmolrot BA,et al.Cogenital cytomegalovirus infection:review of the epidemiology and outcome[J].Obstet Gynecol surv,2002,57:245.
2Boeckh MW,Leisenring SR,Riddell RA,et al.Late cytomegalovirus disease and mortality in allogeneic hematopoietic stem cell transplant recipients:im portance of viral load and T cell im munity[J].Blood,2003,101:407.
4Pellegrin I, Garrigue I, Ekouevi D, et al. New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients. J Infect Dis, 2000, 182(1):36
5Boeckh M,Gallez-Hawkins GM, Myerson D, et al. Plasma polymerase chain reaction for cytomegalorivus and afte allogeneic marrow transplantation. Transplantation, 1997, 64(1):108
6Barrett-muir W,Breuer J, Millar C, et al. CMV viral load measurements in whole blood and plasma-which is best following renal transplantation? Transplantation, 2000, 70(1):116
7Gerna G, Baldanti F, Middeldorp JM, et al. Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung and bone marrow transplant recipients as determined by nucleic acid sequenced-based amplification. J Clin Microbiol, 1999, 37(4):902
8Gerna G, Baldanti F, Lilleri D, et al. Human cytomegalovirus immediate early mRNA detection by nucleic acid sequenced-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients. J Clin Microbiol, 2000, 38(5):1845
9Gerna G, Baldanti F, Lilleri D, et al. Human cytomegalovirus pp67mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients:a prospective randomized controlled open-label trial. Transplantation, 2003, 75(7):1012
10van der Bij W, Speich R. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis, 2001, 33(Suppl 1): S33
